{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:57:34Z","timestamp":1760061454172},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.mcna.2018.02.008","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T13:15:50Z","timestamp":1524748550000},"page":"653-666","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacotherapy for Alcohol Use Disorder"],"prefix":"10.1016","volume":"102","author":[{"given":"Stephen R.","family":"Holt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel G.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2018.02.008_bib1","series-title":"DSM-5 task force. Diagnostic and statistical manual of mental disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.mcna.2018.02.008_bib2","series-title":"2015 national survey on drug use and health: detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2016"},{"key":"10.1016\/j.mcna.2018.02.008_bib3","unstructured":"Department of Health and Human Services. National Institute on Alcohol Abuse and Alcoholism. Alcohol Facts and Statistics. 2017. Available at: https:\/\/pubs.niaaa.nih.gov\/publications\/AlcoholFacts&Stats\/AlcoholFacts&Stats.pdf. Accessed February 1, 2017."},{"issue":"5","key":"10.1016\/j.mcna.2018.02.008_bib4","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","article-title":"2010 national and state costs of excessive alcohol consumption","volume":"49","author":"Sacks","year":"2015","journal-title":"Am J Prev Med"},{"issue":"9859","key":"10.1016\/j.mcna.2018.02.008_bib5","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A\u00a0comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.008_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1525-1497.2006.00405.x","article-title":"The severity of unhealthy alcohol use in hospitalized medical patients. The spectrum is narrow","volume":"21","author":"Saitz","year":"2006","journal-title":"J\u00a0Gen Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.008_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2016.02.003","article-title":"Unhealthy alcohol use","volume":"20","author":"Holt","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.008_bib8","doi-asserted-by":"crossref","first-page":"e0173272","DOI":"10.1371\/journal.pone.0173272","article-title":"Drug therapy for alcohol dependence in primary care in the UK: a clinical practice research Datalink study","volume":"12","author":"Thompson","year":"2017","journal-title":"PLoS One"},{"issue":"1\u20133","key":"10.1016\/j.mcna.2018.02.008_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.drugalcdep.2008.07.018","article-title":"Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty","volume":"99","author":"Mark","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.008_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2015.12.024","article-title":"Growth in spending on substance use disorder treatment services for the privately insured population","volume":"160","author":"Thomas","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.008_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1037\/a0030949","article-title":"Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers","volume":"10","author":"Harris","year":"2013","journal-title":"Psychol Serv"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/alcalc\/agv069","article-title":"Understanding lay assessments of alcohol use disorder: need for treatment and associated stigma","volume":"51","author":"Weine","year":"2016","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/acer.12250","article-title":"Alcohol consumption, heavy drinking, and mortality: rethinking the j-shaped curve","volume":"38","author":"Plunk","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"18","key":"10.1016\/j.mcna.2018.02.008_bib14","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.02.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2015.08.004","article-title":"A\u00a0systematic review on the effectiveness of brief interventions for alcohol misuse among adults in emergency departments","volume":"61","author":"Landy","year":"2016","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.008_bib16","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A\u00a0meta-analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000433579","article-title":"Efficacy of medications approved for the treatment of alcohol dependence and alcohol withdrawal syndrome in female patients: a descriptive review","volume":"22","author":"Agabio","year":"2016","journal-title":"Eur Addict Res"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.008_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11606-014-2968-9","article-title":"An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits","volume":"30","author":"Wei","year":"2015","journal-title":"J\u00a0Gen Intern Med"},{"issue":"04","key":"10.1016\/j.mcna.2018.02.008_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-0042-103592","article-title":"Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence","volume":"49","author":"Mutschler","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"13","key":"10.1016\/j.mcna.2018.02.008_bib20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2014.10152","article-title":"Medications for alcohol use disorders","volume":"312","author":"Saitz","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.02.008_bib21","unstructured":"Pharmacotherapy for adults with alcohol-use disorders in outpatient settings executive summary: Agency for Healthcare Research and Quality. 2014. Available at: https:\/\/effectivehealthcare.ahrq.gov\/topics\/alcohol-misuse-drug-therapy\/clinician. Accessed March 21, 2018."},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib22","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0005-7916(82)90050-7","article-title":"Alcoholism treatment by disulfiram and community reinforcement therapy","volume":"13","author":"Azrin","year":"1982","journal-title":"J\u00a0Behav Ther Exp Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2003.12.006","article-title":"A\u00a0systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction","volume":"74","author":"Roozen","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.008_bib25","unstructured":"Goodrx.com. Disulfiram. Available at: https:\/\/www.goodrx.com\/disulfiram?drug-name=disulfuram. Accessed August 3, 2017."},{"issue":"4","key":"10.1016\/j.mcna.2018.02.008_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate Produces Its Anti-Relapse Effects Via Calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.008_bib28","unstructured":"Goodrx.com. Acamprosate. Available at: https:\/\/www.goodrx.com\/acamprosate?drug-name=acamprosate. Accessed August 3, 2017."},{"key":"10.1016\/j.mcna.2018.02.008_bib29","unstructured":"Substance Abuse and Mental Health Services Administration, National Institute on Alcohol Abuse and Alcoholism. Medication for the treatment of alcohol use disorder: a brief guide. 2015. Available at: https:\/\/store.samhsa.gov\/shin\/content\/\/SMA15-4907\/SMA15-4907.pdf. Accessed August 3, 2017."},{"issue":"3","key":"10.1016\/j.mcna.2018.02.008_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.mcna.2018.02.008_bib31","unstructured":"Revia (naltrexone hydrochloride) Package Insert. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018932s017lbl.pdf. Accessed October 3, 2017."},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib32","first-page":"38","article-title":"Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence","volume":"31","author":"Dean","year":"2006","journal-title":"J\u00a0Psychiatry Neurosci"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/00952990.2010.540281","article-title":"The association between naltrexone treatment and symptoms of depression in opioid-dependent patients","volume":"37","author":"Mysels","year":"2011","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.008_bib34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/acer.13410","article-title":"Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study","volume":"41","author":"Busch","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.mcna.2018.02.008_bib35","series-title":"Vivitrol prescribing information","author":"Alkermes","year":"2013"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsat.2014.03.007","article-title":"Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies","volume":"47","author":"Hartung","year":"2014","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.mcna.2018.02.008_bib37","unstructured":"Goodrx.com. Oral naltrexone. Available at: https:\/\/www.goodrx.com\/naltrexone?drug-name=naltrexone. Accessed March 21, 2018."},{"key":"10.1016\/j.mcna.2018.02.008_bib38","unstructured":"Goodrx.com. Vivitrol. Available at: https:\/\/www.goodrx.com\/vivitrol. Accessed March 21, 2018."},{"issue":"11","key":"10.1016\/j.mcna.2018.02.008_bib39","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.mcna.2018.02.008_bib40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1345\/aph.1L157","article-title":"Topiramate for alcohol dependence","volume":"42","author":"Olmsted","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.008_bib41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.mcna.2018.02.008_bib42","unstructured":"Goodrx.com. Topiramate. Available at: https:\/\/www.goodrx.com\/topiramate?form=tablet&dosage=100mg&quantity=60&days_supply=&label_override=topiramate. Accessed August 3, 2017."},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"7\u20138","key":"10.1016\/j.mcna.2018.02.008_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1345\/aph.1R751","article-title":"Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment","volume":"47","author":"Stock","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.008_bib45","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1530-0277.2009.00986.x","article-title":"A\u00a0double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.008_bib46","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","author":"Leung","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.008_bib47","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.008_bib48","unstructured":"Goodrx.com. Gabapentin. Available at: https:\/\/www.goodrx.com\/gabapentin?drug-name=gabapentin&form=capsule&dosage=300mg&quantity=180&days_supply=&label_override=gabapentin. Accessed August 3, 2017."},{"issue":"11","key":"10.1016\/j.mcna.2018.02.008_bib49","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/1060028014545806","article-title":"Varenicline in the treatment of alcohol use disorders","volume":"48","author":"Erwin","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.008_bib50","first-page":"277","article-title":"A\u00a0double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.mcna.2018.02.008_bib51","unstructured":"Goodrx.com. Varenicline. Available at: https:\/\/www.goodrx.com\/varenicline?drug-name=varenicline. Accessed August 3, 2017."},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0000000000000246","article-title":"Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders","volume":"35","author":"Knapp","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.008_bib53","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40263-016-0390-z","article-title":"Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review","volume":"30","author":"Freynhagen","year":"2016","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.008_bib54","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1177\/0269881109102623","article-title":"Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial","volume":"24","author":"Martinotti","year":"2010","journal-title":"J\u00a0Psychopharmacol"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.008_bib55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.008_bib56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron","volume":"170","author":"Johnson","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib57","first-page":"15","article-title":"Advances in medications and tailoring treatment for alcohol use disorder","volume":"37","author":"Seneviratne","year":"2015","journal-title":"Alcohol Res"},{"key":"10.1016\/j.mcna.2018.02.008_bib58","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","article-title":"Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1year follow-up","volume":"52","author":"Ponizovsky","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.008_bib59","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.euroneuro.2016.10.006","article-title":"Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial","volume":"26","author":"Beraha","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.mcna.2018.02.008_bib60","unstructured":"European Medicines Agency European public assessment report (EPAR) for Selincro. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002583\/human_med_001620.jsp&mid=WC0b01ac058001d124. Accessed August 4, 2017."},{"issue":"5","key":"10.1016\/j.mcna.2018.02.008_bib61","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"113","author":"Palpacuer","year":"2018","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.008_bib63","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","article-title":"A\u00a0double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended release in very heavy drinking alcohol-dependent patients","volume":"36","author":"Fertig","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.008_bib64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JCP.0b013e31825e213e","article-title":"Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: a randomized trial","volume":"32","author":"Richter","year":"2012","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.008_bib65","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A\u00a0double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients","volume":"36","author":"Litten","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","article-title":"A\u00a0randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence","volume":"28","author":"Anton","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.09.004","article-title":"Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis","volume":"78","author":"Torrens","year":"2005","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib68","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","article-title":"Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety","volume":"37","author":"Litten","year":"2016","journal-title":"Subst Abus"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.008_bib69","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1530-0277.2007.00360.x","article-title":"A\u00a0pilot double-blind treatment trial of memantine for alcohol dependence","volume":"31","author":"Evans","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.008_bib70","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"issue":"17","key":"10.1016\/j.mcna.2018.02.008_bib71","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.008_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.008_bib73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.008_bib74","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/appi.ajp.2010.08101500","article-title":"Medication treatment of different types of alcoholism","volume":"167","author":"Johnson","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.008_bib75","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.clinthera.2013.07.157","article-title":"PP135\u2014Pharmacometabolomics for individualized treatment of alcoholism: high serum glutamate level is associated with positive response to acamprosate treatment","volume":"35","author":"Choi","year":"2013","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.mcna.2018.02.008_bib76","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/jama.2009.535","article-title":"Findings on alcohol dependence point to promising avenues for targeted therapies","volume":"301","author":"Kuehn","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.02.008_bib77","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pnpbp.2015.07.011","article-title":"Alcohol addiction and the mu-opioid receptor","volume":"65","author":"Berrettini","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.008_bib78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch Gen Psychiatry"},{"issue":"14","key":"10.1016\/j.mcna.2018.02.008_bib79","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1001\/archinte.163.14.1695","article-title":"Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials","volume":"163","author":"O'Malley","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2018.02.008_bib80","unstructured":"U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment. Incorporating alcohol pharmacotherapies into medical practice: a treatment improvement protocol. TIP 49. Available at: https:\/\/store.samhsa.gov\/shin\/content\/\/SMA13-4380\/SMA13-4380.pdf. Accessed August 4, 2017."}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T23:05:24Z","timestamp":1534201524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518300129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0025712518300129"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.008","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for Alcohol Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}